Mainz Biomed B.V. ( (MYNZ) ) has provided an update.
Mainz Biomed N.V. announced its 2024 financial results and corporate updates, highlighting a 33% increase in lab network revenue due to strong demand for ColoAlert® in Europe. The company reported a decrease in operating and net losses by 30% and 18%, respectively, attributed to cost reductions and strategic focus. Key accomplishments in 2024 included collaborations with Thermo Fisher Scientific and Quest Diagnostics for developing next-generation cancer screening products and clinical trials. Mainz Biomed also regained compliance with Nasdaq listing requirements and initiated the eAArly DETECT 2 study to validate its next-generation colorectal cancer test. Early 2025 updates include a license agreement with Liquid Biosciences for pancreatic cancer detection and the enrollment of the first patient in the eAArly DETECT 2 study.
More about Mainz Biomed B.V.
Mainz Biomed N.V. is a molecular genetics diagnostic company specializing in the early detection of cancer. The company focuses on developing and commercializing innovative diagnostic solutions, with a significant market presence in Europe through its ColoAlert® product, a colorectal cancer screening test.
YTD Price Performance: -25.35%
Average Trading Volume: 221,442
Technical Sentiment Signal: Buy
Current Market Cap: $7.95M
See more data about MYNZ stock on TipRanks’ Stock Analysis page.